Turkey weighing citizens in public to fight obesity, critics slam the move as fat shaming
Turkey is tipping the scales in its war on obesity.
The country has launched a nationwide campaign to measure citizens' weight in public spaces to combat its rising obesity rates — a move critics argue amounts to public fat shaming and government overreach.
The initiative, called "Learn Your Ideal Weight, Live Healthy" campaign, will see around 10 million people assessed between May 10 and July 10. If they are deemed overweight, they will be directed to health centers to receive nutritional counseling and monitoring by dietitians, according to Turkish Minute.
The controversial move aims to raise awareness about chronic weight dangers and to promote healthier lifestyles.
Obesity Most Prevalent In These 3 Southern Cities
Turkish Health Minister Kemal Memişoğlu introduced the initiative earlier this month, stating that health personnel would take measurements in public areas across all 81 provinces, Turkish media reported.
Read On The Fox News App
Various images posted to social media by Turkey's health ministry show health officials taking people's height measurements before guiding them onto weighing scales at so-called check points in public spaces.
Individuals have their body weight and height measured to calculate their body mass index (BMI), a simple calculation used to assess whether a person has a healthy body weight for their height.
If someone has a BMI of 25 or higher, they will be referred to the health centers.
The initiative has drawn backlash, with critics slamming it as invasive, stigmatizing and essentially amounting to fat shaming in public. Other detractors argue that the government is not addressing broader contributing factors such as soaring food prices, stagnant wages and limited access to affordable nutrition.
Fresh Food Consumption Could Help Solve Diet-related Illness: Experts
Gökben Hızlı Sayar, a Turkish psychiatrist and academic, likened the stations to fat check points and said she was forced to get measured.
"I got caught in a fat car showdown in Üsküdar Square, she wrote on X last week. "Luckily, they reprimanded me a little and let me go. When I saw the radar, I warned 3 fat people who were going that way to flash their headlights at each other. Today is the day of unity, my fat brothers."
The health minister, however, said the goal is to inform the public and make them healthier.
In an effort to lead by example, Memişoğlu himself was measured and revealed that he is over the limit, although it wasn't clear by how much.
"Which dietitian should I go to?" he humorously said to reporters before later adding, "turns out I'm a little over. It's up to me now, I'll be walking every day," Turkish Minute reported.
Memişoğlu also posted video of himself walking, writing, "it's time to get down to business, we'll walk every day."
Turkey has a population of around 85 million people and around 32.1% are considered obese, according to the World Health Organization. Anyone over a BMI of 30 is considered obese.
That rate is still lower than in the United States, where the most recent studies by the CDC show obesity among adults at 40.3%.
Experts link the rate in Turkey to rising fast-food consumption, economic barriers to healthy food and urbanization reducing physical activity levels, according to Turkey Today.Original article source: Turkey weighing citizens in public to fight obesity, critics slam the move as fat shaming
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Federal judge rules Trump admin cannot block grants to LGBT groups
A federal judge in California ruled on Monday that the Trump administration cannot enforce executive orders that require groups to halt programs that promote diversity, equity and inclusion or acknowledge the existence of transgender people to receive grant funding. U.S. District Judge Jon Tigar wrote in his order that a group of pro-LGBTQ nonprofits "demonstrated that they likely have standing to challenge" several provisions in President Donald Trump's executive orders, which the groups argue violate the Constitution. "These three funding provisions reflect an effort to censor constitutionally protected speech and services promoting DEI and recognizing the existence of transgender individuals," the judge wrote in his order. Tigar said that while the executive branch "requires some degree of freedom to implement its political agenda, it is still bound by the Constitution," and "cannot weaponize Congressionally appropriated funds to single out protected communities for disfavored treatment or suppress ideas that it does not like or has deemed dangerous." Npr Sues Trump White House Over Executive Order Targeting Public Media Lawyers for the government say that the president is permitted to "align government funding and enforcement strategies" with his policies. Read On The Fox News App Plaintiffs say that Congress — and not the president — has the power to condition how federal funds are used, and that the executive orders restrict free speech rights. Federal Judge Rules Against Trump Order Halting Sex Change Procedures In Prisons The plaintiffs include health centers, LGBTQ+ services groups, the Gay Lesbian Bisexual Transgender Historical Society and the San Francisco AIDS Foundation. The groups are all recipients of federal funding and say that following the executive orders will prevent them from completing their missions. The judge's order will remain in effect while the legal case continues, although government lawyers will likely appeal. The Associated Press contributed to this article source: Federal judge rules Trump admin cannot block grants to LGBT groups
Yahoo
2 hours ago
- Yahoo
Multi-Blood Monitoring System Market is expected to reach USD 3.9 billion by 2034, with a 6.4% CAGR growth
Multi Blood Monitoring System Market Overview 2025-2034 Luton, Bedfordshire, United Kingdom, June 10, 2025 (GLOBE NEWSWIRE) -- The global multi blood monitoring system market is witnessing dynamic expansion, with its value estimated at approximately USD 2.1 billion in 2024, and expected to grow to around USD 3.9 billion by 2034. This translates into a Compound Annual Growth Rate (CAGR) of 6.4% over the forecast period from 2025 to 2034. This growth is primarily fueled by the increasing demand for accurate, efficient, and accessible blood monitoring technologies across various healthcare applications. Download PDF Brochure: These devices are critical in the management of chronic diseases such as diabetes and cardiovascular conditions. As the global burden of such illnesses escalates, particularly among aging populations and across developing regions, the need for real-time, portable, and user-friendly blood monitoring systems has become more urgent than ever. Market Drivers and Opportunities Several underlying factors are contributing to the expansion of this market. Among the most significant drivers is the rising prevalence of chronic diseases. The World Health Organization (WHO) forecasts that by 2030, chronic diseases will account for over 75% of global deaths, highlighting the growing necessity for continuous and reliable health monitoring tools. Moreover, technological advancements in wearable devices, mobile health apps, and telemedicine have revolutionized the way blood monitoring is conducted. These innovations have led to more personalized and preventive healthcare solutions, allowing patients to self-monitor in real-time, often without the need for clinical supervision. This trend is particularly appealing to tech-savvy consumers and younger demographics who are increasingly proactive about their health. Emerging economies also present significant growth potential. With rising healthcare expenditure, expanding middle-class populations, and improving medical infrastructure, regions such as Asia-Pacific, Latin America, and parts of the Middle East are becoming fertile grounds for market expansion. Additionally, the integration of AI and machine learning into monitoring systems is creating opportunities for predictive diagnostics and tailored treatment strategies, revolutionizing the future of personalized medicine. Key Market Challenges Despite its positive growth outlook, the multi blood monitoring system market faces certain challenges. One of the primary obstacles is the complex regulatory landscape. Medical device manufacturers must navigate stringent approval processes, especially in developed regions like North America and Europe. These regulations, although necessary for ensuring safety and efficacy, often delay product rollouts and increase development costs. Supply chain disruptions have also impacted the market, particularly during and after the COVID-19 pandemic. Delays in procuring raw materials, component shortages, and transportation hurdles have affected production timelines and product availability. Furthermore, high costs associated with technologically advanced blood monitoring devices can be a deterrent for adoption, especially in price-sensitive markets. Healthcare providers are often pressured to deliver cost-effective solutions, which can limit investments in premium monitoring systems. Another pressing concern is data security and patient privacy. With the growing digitalization of healthcare and increased reliance on cloud-based data storage, ensuring the protection of sensitive patient information has become paramount. Regulatory frameworks such as HIPAA and GDPR are placing additional burdens on companies to fortify their cybersecurity measures. Market Segmentation Analysis By Product Type The market is segmented into several product categories including continuous glucose monitoring (CGM) systems, blood pressure monitors, cholesterol testing devices, and complete blood count (CBC) test devices. Among these, CGM systems are emerging as the dominant product category, accounting for roughly 35% of market share. The increased prevalence of diabetes globally has significantly contributed to this trend. Blood pressure monitoring devices come in second, capturing an estimated 25% of the market, owing to the widespread incidence of hypertension. Cholesterol testing devices follow with a 15% market share, as more individuals become aware of the risks associated with high cholesterol levels. By End User Hospitals are the largest consumers of multi blood monitoring systems, accounting for nearly 45% of the market share. The growing number of patients and a strong focus on preventive healthcare are driving demand in this segment. Diagnostic laboratories represent the second-largest user group, contributing 30% of market revenue, largely due to the complexity and volume of testing they handle. Homecare settings have gained traction, especially post-pandemic, and currently hold around 20% of the market. The convenience of remote monitoring has been widely appreciated, particularly among the elderly and chronically ill patients who prefer in-home testing. By Technology From a technology standpoint, wearable technologies are transforming the landscape, projected to represent 40% of the market by 2034. These devices offer unmatched convenience and user engagement. Invasive technologies still maintain a solid 45% market share, particularly in clinical environments where precision is critical. Meanwhile, non-invasive technologies are growing steadily and are expected to hold 15% of the market, driven by advancements in optical and sensor-based innovations. By Application Diabetes management remains the top application area, constituting about 50% of the total market. As diabetes rates continue to climb worldwide, the demand for continuous and accurate glucose monitoring devices is increasing proportionally. Cardiovascular monitoring is another important application, making up 30% of the market, while fitness and wellness monitoring is growing rapidly, accounting for around 15% as consumers adopt proactive health strategies. By Distribution Channel In terms of distribution, offline sales still dominate with a 55% market share, primarily due to the preference for in-person consultations and product demonstrations in hospital and clinical settings. Online channels, however, are growing fast and now represent 30% of sales, fueled by digital adoption and e-commerce growth. Direct sales—through specialized distributors—comprise the remaining 15%, ensuring product customization and support services. Browse full Report - Market Segmentation Product Type - Continuous Glucose Monitoring Systems - Blood Pressure Monitoring Devices - Cholesterol Testing Devices - Complete Blood Count Test Devices - Others End-User - Hospitals - Diagnostic Laboratories - Homecare Settings - Research Institutions Technology - Wearable Technology - Non-invasive Technology - Invasive Technology Application - Diabetes Management - Cardiovascular Monitoring - Blood Disorders Management - Fitness and Wellness Monitoring Distribution Channel - Online Sales - Offline Sales - Direct Sales Region - North America - Europe - Asia Pacific - Latin America - Middle East & Africa Regional Outlook Regionally, North America leads the global market, accounting for approximately 40% of total revenues in 2024. This dominance is attributed to advanced healthcare infrastructure, favorable regulatory support, and the presence of leading industry players. Europe follows with a 30% market share, supported by robust public healthcare systems and a rising focus on personalized medicine. The Asia-Pacific region is the fastest-growing market, projected to expand at a CAGR of 7.5%. This growth is driven by large patient populations, increasing disposable income, and government initiatives to enhance healthcare access. Countries such as China, India, and Japan are key contributors to this growth trajectory. Latin America and the Middle East & Africa collectively account for a modest share (5% in 2024) but are poised for steady growth due to improvements in healthcare infrastructure and expanding awareness about chronic disease management. Key Competitors Abbott Laboratories Roche Holding AG Siemens Healthineers Becton, Dickinson and Company (BD) Medtronic plc Nova Biomedical Johnson & Johnson Dexcom, Inc. Arkray, Inc. Ascensia Diabetes Care Terumo Corporation GlySens Incorporated Insulet Corporation Elysium Health LabCorp Recent Industry Developments Several companies have made notable strides in advancing this market: Abbott Laboratories launched FreeStyle Libre 3, a real-time glucose monitor with a discreet sensor, in June 2023, strengthening its lead in the CGM space. In April 2023, Roche formed a strategic partnership with a wearable tech firm to integrate blood monitoring devices with smart devices, enhancing patient engagement and adherence. Siemens Healthineers acquired an AI-based diagnostics company in August 2023, signaling a deeper focus on precision diagnostics through data analytics. Dexcom received FDA approval in September 2023 for a no-fingerstick CGM device, which is likely to broaden its user base and redefine market standards. Medtronic expanded its product line into Asia and Africa in July 2023, targeting underserved markets and accelerating growth in emerging economies. This report is also available in the following languages : Japanese (マルチ血液モニタリングシステム市場), Korean (다혈액 모니터링 시스템 시장), Chinese (多血液监测系统市场), French (Marché des systèmes de surveillance sanguine multi-sang), German (Markt für Multi-Blutüberwachungssysteme), and Italian (Mercato dei sistemi di monitoraggio multi-sangue), etc. Request Sample Pages: More Research Finding – Medical Refrigerated Market The global medical refrigerated market is valued at approximately $6.5 billion in 2024, with projections indicating a potential increase to around $10 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of approximately 4.5% during the forecast period from 2025 to 2034. Cardiovascular Monitoring Devices Market The cardiovascular monitoring devices market is valued at approximately $10.5 billion in 2024, with projections indicating substantial growth, reaching around $16.8 billion by 2034. This translates to a robust Compound Annual Growth Rate (CAGR) of approximately 4.8% during the forecast period from 2025 to 2034. Non Invasive Hemodynamic Detection System Market The global Non-Invasive Hemodynamic Detection System market is valued at approximately USD 2.1 billion in 2024, with strong growth anticipated over the next decade. By 2034, the market is projected to reach around USD 4.5 billion, representing a Compound Annual Growth Rate (CAGR) of approximately 8.0%. Disposable Syringes and Accessories Market The global disposable syringes and accessories market is valued at approximately $7.5 billion in 2024, with a projected growth trajectory that anticipates reaching around $13 billion by 2034. This translates to a compound annual growth rate (CAGR) of about 6.1% over the 2025-2034 period. Blood Collection Mixer Market The blood collection mixer market is valued at approximately $250 million in 2024 and is projected to reach around $400 million by 2034. This growth represents a Compound Annual Growth Rate (CAGR) of about 5.1% during the forecast period from 2025 to 2034. Hemochromatosis Treatment Market The global hemochromatosis treatment market is valued at approximately $2.1 billion in 2024. The market is anticipated to grow significantly, reaching an estimated $3.5 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period of 2025–2034. Gestational Trophoblastic Disease Market The gestational trophoblastic disease (GTD) market is currently valued at approximately $1.8 billion in 2024, with projections indicating a potential growth to around $3.1 billion by 2034. This represents a compound annual growth rate (CAGR) of approximately 6.2% during the forecast period from 2025 to 2034. Septicemia Diagnostic Market The global septicemia diagnostics market is valued at approximately $1.5 billion in 2024, with projections indicating a growth to around $2.9 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 7.5% for the period from 2025 to 2034. Single Use Safety Lancet Market The global market for single-use safety lancets, valued at approximately $1.2 billion in 2024, is expected to reach around $2.5 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.7% during the forecast period from 2025 to 2034. Microalbuminuria Test Strip Market The microalbuminuria test strip market is poised for notable growth, valued at approximately $1.2 billion in 2024. This market is projected to expand to around $2.4 billion by 2034, indicating a robust growth trajectory. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is estimated at 7.3%. Monkeypox Virus Detection Reagent Market The monkeypox virus detection reagent market is anticipated to reach approximately $150 million in value by 2024, driven by heightened awareness and diagnostic needs amid ongoing public health surveillance. The market is projected to expand significantly, reaching an estimated $300 million by 2034, reflecting sustained interest in infectious disease diagnostics and preparedness. Blood Tester Market The global blood testing market is anticipated to reach a value of approximately $75 billion in 2024, driven by increasing prevalence of chronic diseases, rising health awareness, and advancements in diagnostic technologies. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% from 2025 to 2034, potentially reaching over $135 billion by 2034. HBsAg ELISA Test Kit Market The HBsAg ELISA Test Kit market is poised for robust growth, with a current market value estimated at approximately $1.5 billion in 2024. Driven by the increasing global prevalence of Hepatitis B, ongoing advancements in diagnostic technologies, and rising healthcare expenditures, the market is projected to reach around $2.8 billion by 2034. This trajectory indicates a Compound Annual Growth Rate (CAGR) of approximately 6.5% from 2025 to 2034. Blood Plasma Extractor Market The global blood plasma extractor market is valued at approximately $1.2 billion, driven by rising demand for plasma-derived therapies in treating various diseases. The market is projected to reach about $2.9 billion by 2034, reflecting an impressive Compound Annual Growth Rate (CAGR) of approximately 9.2% from 2025 to 2034. Amphetamine Test Kit Market The amphetamine test kit market is projected to reach a value of approximately $500 million in 2024, with expectations to grow to around $900 million by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of 6% during the forecast period of 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Merz hails BioNTech founders' 'courage' as they receive German prize
The co-founders of German drugmaker BioNTech, which was one of the first companies to develop an effective vaccine against the coronavirus, were honoured with Germany's National Prize on Tuesday. In his laudatory speech, Chancellor Friedrich Merz hailed Özlem Türeci and Ugur Sahin for their "extraordinary courage". "You both embody the future strength of a liberal society. As scientists who seek solutions. But also as entrepreneurs for whom responsibility is at the centre of their work," Merz said during the award ceremony held at Berlin's Französische Friedrichstadtkirche church. The two scientists, who specialize in the development of immunotherapies against cancer, infectious diseases and diseases of the immune and nervous system, developed a coronavirus vaccine in 2020, over the course of less than a year. Merz also praised the two researchers, who have Turkish roots, as examples of the importance of "skilled labour immigration as a driver of progress." "I want to live in a Germany in which talent is promoted to the best of our ability, regardless of social or ethnic background," said Merz. Ideologies calling this tenet into question jeopardize "the future of our liberal order with their narrow-mindedness," the German leader said. The German National Prize has been awarded by the German National Foundation since 1997 to individuals or organizations for their efforts to a democratic society. The award is endowed with a total of €50,000 ($57,000). The German National Foundation was established by former chancellor Helmut Schmidt and friends in 1993.